Olema Pharmaceuticals, Inc. (OLMA)
NasdaqGS: OLMA
· 即時價格 · USD
10.22
-0.47 (-4.40%)
收盤價： Sep 11, 2026, 3:59 PM
8.76
-14.32%
盤後: 7:58 PM
股價、關鍵數字和最新消息，都在這一頁。
Olema Pharmaceuticals, Inc.（OLMA）股價、分析與資料
-4.40% (1D)
| 買價 | 7.63 |
| 市值 | 894M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -205M |
| 1.99 | |
| -2.12 | |
| n/a | |
| -3.8 | |
| P/B (ttm) | 2.08 |
| P/S (ttm) | 0.00 |
| 財報日期 | Nov 9, 2026 |
| 賣價 | 13.06 |
| 成交量 | 895,248 |
| 20 日平均成交量 | 1,255,212 |
| 開盤價 | 10.79 |
| 前收盤價 | 10.69 |
| 當日區間 | 10.18 - 10.86 |
| 52 週範圍 | 6.65 - 36.26 |
| 分析師 | n/a |
| 目標價 | 40 (291.39%) |
| 股利 | n/a |
| 除息日 | n/a |
關於 OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative ...
完整的公司簡介財報驚奇
Olema Pharmaceuticals 已於 Aug 10, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.61 低於預期 -0.05, 年增 -19.61% 下滑.
第 1 頁，共 2 頁